The daily use of specific antiretroviral medications by persons without HIV infection, but at high risk exposure, has been shown to be a safe and effective HIV prevention method. The FDA approved Truvada® for preexposure prophylaxis (PrEP) in July 2012 and Public Health Services has issued clinical practice guidelines for its use. CDC requests approval to collect data to be used to conduct research about clinician knowledge, attitudes, and practices related to PrEP over the period of its initial introduction in their clinics. The knowledge will be used to refine measurement instruments and methods, develop training and educational resources and tools for use by CDC-funded partners, and other organizations supporting delivery of PrEP in clinical settings. This change request is to change two of the clinic sites and add a few more respondents with minimal change in burden.
This request is for a minor increase in respondents, from 175 to 200, and changing two of the clinic sites to other cities. There is a minor change in burden from 88 to 100 hours.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.